Second-generation antiandrogens in nonmetastatic CRPC

被引：4

作者：

Chandler, Robert ^{[1
,2
]}

de Bono, Johann ^{[1
,2
]}

机构：

[1] Inst Canc Res, Div Clin Studies, Sutton, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Prostate Canc Targeted Therapy Grp, Sutton, Surrey, England

来源：

NATURE REVIEWS UROLOGY | 2018年 / 15卷 / 06期

关键词：

PROSTATE-CANCER;

D O I：

10.1038/s41585-018-0007-z

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The FDA recently approved the second-generation antiandrogen apalutamide for the treatment of men with nonmetastatic castration-resistant prostate cancer on the basis of metastasis-free survival data from the SPARTAN trial. However, whether apalutamide is clinically superior to enzalutamide and whether early or late treatment is preferable remains to be defined.

引用

页码：342 / 344

页数：4

共 10 条

[1] Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting [J].

Antonarakis, E. S. ;

Armstrong, A. J. ;

Dehm, S. M. ;

Luo, J. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2016, 19 (03) :231-241

[2] Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to Recurrence [J].

Boorjian, Stephen A. ;

Thompson, R. Houston ;

Tollefson, Matthew K. ;

Rangel, Laureano J. ;

Bergstralh, Eric J. ;

Blute, Michael L. ;

Karnes, R. Jeffrey .

EUROPEAN UROLOGY, 2011, 59 (06) :893-899

[3] ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment [J].

Clegg, Nicola J. ;

Wongvipat, John ;

Joseph, James D. ;

Tran, Chris ;

Ouk, Samedy ;

Dilhas, Anna ;

Chen, Yu ;

Grillot, Kate ;

Bischoff, Eric D. ;

Cal, Ling ;

Aparicio, Anna ;

Dorow, Steven ;

Arora, Vivek ;

Shao, Gang ;

Qian, Jing ;

Zhao, Hong ;

Yang, Guangbin ;

Cao, Chunyan ;

Sensintaffar, John ;

Wasielewska, Teresa ;

Herbert, Mark R. ;

Bonnefous, Celine ;

Darimont, Beatrice ;

Scher, Howard I. ;

Smith-Jones, Peter ;

Klang, Mark ;

Smith, Nicholas D. ;

De Stanchina, Elisa ;

Wu, Nian ;

Ouerfelli, Ouathek ;

Rix, Peter J. ;

Heyman, Richard A. ;

Jung, Michael E. ;

Sawyers, Charles L. ;

Hager, Jeffrey H. .

CANCER RESEARCH, 2012, 72 (06) :1494-1503

[4] Death in patients with recurrent prostate cancer after radical prostatectomy: Prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality [J].

Freedland, Stephen J. ;

Humphreys, Elizabeth B. ;

Mangold, Leslie A. ;

Eisenberger, Mario ;

Dorey, Frederick J. ;

Walsh, Patrick C. ;

Partin, Alan W. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) :1765-1771

[5] PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). [J].

Hussain, Maha ;

Fizazi, Karim ;

Saad, Fred ;

Rathenborg, Per ;

Shore, Neal D. ;

Demirhan, Eren ;

Modelska, Katharina ;

De Phung ;

Krivoshik, Andrew ;

Sternberg, Cora N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)

[6] Review of Salvage Therapy for Biochemically Recurrent Prostate Cancer: The Role of Imaging and Rationale for Systemic Salvage Targeted Anti-Prostate-Specific Membrane Antigen Radioimmunotherapy [J].

Kosuri, Satyajit ;

Akhtar, Naveed H. ;

Smith, Michael ;

Osborne, Joseph R. ;

Tagawa, Scott T. .

ADVANCES IN UROLOGY, 2012, 2012

[7] Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis [J].

Scher, HI ;

Sawyers, CL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (32) :8253-8261

[8] Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer [J].

Smith, Matthew R. ;

Saad, Fred ;

Chowdhury, Simon ;

Oudard, Stephane ;

Hadaschik, Boris A. ;

Graff, Julie N. ;

Olmos, David ;

Mainwaring, Paul N. ;

Lee, Ji Youl ;

Uemura, Hiroji ;

Lopez-Gitlitz, Angela ;

Trudel, Geralyn C. ;

Espina, Byron M. ;

Shu, Youyi ;

Park, Youn C. ;

Rackoff, Wayne R. ;

Yu, Margaret K. ;

Small, Eric J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (15) :1408-1418

[9] Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer [J].

Tran, Chris ;

Ouk, Samedy ;

Clegg, Nicola J. ;

Chen, Yu ;

Watson, Philip A. ;

Arora, Vivek ;

Wongvipat, John ;

Smith-Jones, Peter M. ;

Yoo, Dongwon ;

Kwon, Andrew ;

Wasielewska, Teresa ;

Welsbie, Derek ;

Chen, Charlie Degui ;

Higano, Celestia S. ;

Beer, Tomasz M. ;

Hung, David T. ;

Scher, Howard I. ;

Jung, Michael E. ;

Sawyers, Charles L. .

SCIENCE, 2009, 324 (5928) :787-790

[10] Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer [J].

Xie, Wanling ;

Regan, Meredith M. ;

Buyse, Marc ;

Halabi, Susan ;

Kantoff, Philip W. ;

Sartor, Oliver ;

Soule, Howard ;

Clarke, Noel W. ;

Collette, Laurence ;

Dignam, James J. ;

Fizazi, Karim ;

Paruleker, Wendy R. ;

Sandler, Howard M. ;

Sydes, Matthew R. ;

Tombal, Bertrand ;

Williams, Scott G. ;

Sweeney, Christopher J. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (27) :3097-3104

← 1 →